Armata Pharmaceuticals 3Q 2026: Revenue $3.17M, EPS ($0.24) — 10-Q Summary
Armata Pharmaceuticals reported 3Q 2026 revenue of $3.17M, up 173.6% YoY, and net income of $42.64M, reversing a prior-year loss. The gain was driven by higher grant revenue and a $69.6M increase in the fair value of the Convertible Loan, offset by increased expenses. FDA granted Breakthrough Therapy designation for AP-SA02, and Phase 3 preparation is underway.
How this was made

The 30-second read
Why it matters
The earnings beat could attract speculative buying, but sustainability is uncertain.
Market read
Micro‑cap biotech earnings surprise with profit swing; potential short‑term trade opportunity.
What to watch
Increased operating and interest expenses could pressure future profitability.
Background
Armata Pharmaceuticals filed its 10‑Q for Q3 2026, highlighting a dramatic profit swing.
Ticker impact
10-Q shows revenue $3.17M and net income $42.64M, a swing to profit and positive EPS.
potential upside as market prices in profit swing
First report of quarterly profit and EPS improvement for a micro‑cap biotech.
Market effects
May boost sentiment in the biotech/clinical‑trial sector.
Limited to U.S. biotech investors.
Low global impact beyond niche investors.
Counterpoint
Profit may be one‑off due to fair‑value gain on convertible loan; underlying cash burn remains high.
Key entities
- companyArmata Pharmaceuticals
Biotech firm reporting Q3 2026 results.

